RHOEN-KLINIKUM AG (RHK.DE) Fundamental Analysis & Valuation

FRA:RHK • DE0007042301

13.1 EUR
+0.1 (+0.77%)
Last: Mar 11, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This RHK.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, RHK scores 5 out of 10 in our fundamental rating. RHK was compared to 33 industry peers in the Health Care Providers & Services industry. While RHK has a great health rating, its profitability is only average at the moment. RHK is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. RHK.DE Profitability Analysis

1.1 Basic Checks

  • In the past year RHK was profitable.
  • In the past year RHK had a positive cash flow from operations.
  • Each year in the past 5 years RHK has been profitable.
  • In the past 5 years RHK always reported a positive cash flow from operatings.
RHK.DE Yearly Net Income VS EBIT VS OCF VS FCFRHK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 2.02%, RHK is doing worse than 60.61% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 2.90%, RHK is doing worse than 66.67% of the companies in the same industry.
  • RHK has a worse Return On Invested Capital (2.67%) than 69.70% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for RHK is below the industry average of 6.06%.
  • The 3 year average ROIC (2.34%) for RHK is below the current ROIC(2.67%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.02%
ROE 2.9%
ROIC 2.67%
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
RHK.DE Yearly ROA, ROE, ROICRHK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6

1.3 Margins

  • The Profit Margin of RHK (2.28%) is comparable to the rest of the industry.
  • In the last couple of years the Profit Margin of RHK has declined.
  • RHK has a worse Operating Margin (2.86%) than 63.64% of its industry peers.
  • RHK's Operating Margin has declined in the last couple of years.
  • With a decent Gross Margin value of 66.81%, RHK is doing good in the industry, outperforming 72.73% of the companies in the same industry.
  • In the last couple of years the Gross Margin of RHK has remained more or less at the same level.
Industry RankSector Rank
OM 2.86%
PM (TTM) 2.28%
GM 66.81%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
RHK.DE Yearly Profit, Operating, Gross MarginsRHK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RHK.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RHK is destroying value.
  • The number of shares outstanding for RHK remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, RHK has about the same amount of shares outstanding.
  • RHK has a better debt/assets ratio than last year.
RHK.DE Yearly Shares OutstandingRHK.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RHK.DE Yearly Total Debt VS Total AssetsRHK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 3.09 indicates that RHK is not in any danger for bankruptcy at the moment.
  • RHK has a better Altman-Z score (3.09) than 81.82% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that RHK is not too dependend on debt financing.
  • The Debt to Equity ratio of RHK (0.09) is better than 96.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.09
ROIC/WACC0.4
WACC6.62%
RHK.DE Yearly LT Debt VS Equity VS FCFRHK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 2.28 indicates that RHK has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 2.28, RHK belongs to the best of the industry, outperforming 93.94% of the companies in the same industry.
  • A Quick Ratio of 2.19 indicates that RHK has no problem at all paying its short term obligations.
  • RHK has a better Quick ratio (2.19) than 93.94% of its industry peers.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.19
RHK.DE Yearly Current Assets VS Current LiabilitesRHK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RHK.DE Growth Analysis

3.1 Past

  • RHK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.41%.
  • RHK shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.03% yearly.
  • The Revenue has grown by 9.10% in the past year. This is quite good.
  • RHK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.12% yearly.
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%

3.2 Future

  • RHK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.55% yearly.
  • Based on estimates for the next years, RHK will show a small growth in Revenue. The Revenue will grow by 5.92% on average per year.
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.55%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y5.92%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RHK.DE Yearly Revenue VS EstimatesRHK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B 2B
RHK.DE Yearly EPS VS EstimatesRHK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

2

4. RHK.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 22.98, RHK is valued on the expensive side.
  • RHK's Price/Earnings ratio is a bit more expensive when compared to the industry. RHK is more expensive than 69.70% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.15. RHK is around the same levels.
  • With a Price/Forward Earnings ratio of 17.14, RHK is valued on the expensive side.
  • RHK's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. RHK is more expensive than 69.70% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.27, RHK is valued a bit cheaper.
Industry RankSector Rank
PE 22.98
Fwd PE 17.14
RHK.DE Price Earnings VS Forward Price EarningsRHK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RHK is valued cheaper than 96.97% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.51
RHK.DE Per share dataRHK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RHK does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)5.34
PEG (5Y)675.83
EPS Next 2Y10.47%
EPS Next 3Y11.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. RHK.DE Dividend Analysis

5.1 Amount

  • RHK has a yearly dividend return of 0.78%, which is pretty low.
  • RHK's Dividend Yield is comparable with the industry average which is at 1.61.
  • With a Dividend Yield of 0.78, RHK pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.78%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
RHK.DE Yearly Dividends per shareRHK.DE Yearly Dividends per shareYearly Dividends per share 2019 2023 2025 0.05 0.1 0.15 0.2 0.25

5.3 Sustainability

  • 17.78% of the earnings are spent on dividend by RHK. This is a low number and sustainable payout ratio.
DP17.78%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
RHK.DE Yearly Income VS Free CF VS DividendRHK.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M
RHK.DE Dividend Payout.RHK.DE Dividend Payout, showing the Payout Ratio.RHK.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

RHK.DE Fundamentals: All Metrics, Ratios and Statistics

RHOEN-KLINIKUM AG

FRA:RHK (3/11/2026, 7:00:00 PM)

13.1

+0.1 (+0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06
Earnings (Next)03-26
Inst Owners0.53%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap877.18M
Revenue(TTM)1.69B
Net Income(TTM)37.68M
Analysts74.29
Price Target14.45 (10.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.78%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP17.78%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 22.98
Fwd PE 17.14
P/S 0.53
P/FCF N/A
P/OCF 14.22
P/B 0.68
P/tB 0.78
EV/EBITDA 0.51
EPS(TTM)0.57
EY4.35%
EPS(NY)0.76
Fwd EY5.83%
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)0.92
OCFY7.03%
SpS24.7
BVpS19.41
TBVpS16.81
PEG (NY)5.34
PEG (5Y)675.83
Graham Number15.78
Profitability
Industry RankSector Rank
ROA 2.02%
ROE 2.9%
ROCE 3.25%
ROIC 2.67%
ROICexc 4.45%
ROICexgc 5.55%
OM 2.86%
PM (TTM) 2.28%
GM 66.81%
FCFM N/A
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
ROICexc(3y)3.1%
ROICexc(5y)2.62%
ROICexgc(3y)3.7%
ROICexgc(5y)3.13%
ROCE(3y)2.85%
ROCE(5y)2.44%
ROICexgc growth 3Y17.7%
ROICexgc growth 5Y-1.56%
ROICexc growth 3Y17.75%
ROICexc growth 5Y-1.75%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
F-Score6
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA 1.07
Cap/Depr 112.99%
Cap/Sales 4.21%
Interest Coverage 14.78
Cash Conversion 56.66%
Profit Quality N/A
Current Ratio 2.28
Quick Ratio 2.19
Altman-Z 3.09
F-Score6
WACC6.62%
ROIC/WACC0.4
Cap/Depr(3y)97.27%
Cap/Depr(5y)108.32%
Cap/Sales(3y)4.24%
Cap/Sales(5y)5.08%
Profit Quality(3y)86.55%
Profit Quality(5y)290.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.55%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y5.92%
EBIT growth 1Y2.05%
EBIT growth 3Y16.29%
EBIT growth 5Y-3.2%
EBIT Next Year147.27%
EBIT Next 3Y44.19%
EBIT Next 5Y27.95%
FCF growth 1Y26.17%
FCF growth 3Y42.66%
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3Y9.38%
OCF growth 5Y21.95%

RHOEN-KLINIKUM AG / RHK.DE FAQ

Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?

ChartMill assigns a fundamental rating of 5 / 10 to RHK.DE.


What is the valuation status of RHOEN-KLINIKUM AG (RHK.DE) stock?

ChartMill assigns a valuation rating of 2 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.


Can you provide the profitability details for RHOEN-KLINIKUM AG?

RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 4 / 10.


Can you provide the financial health for RHK stock?

The financial health rating of RHOEN-KLINIKUM AG (RHK.DE) is 7 / 10.


How sustainable is the dividend of RHOEN-KLINIKUM AG (RHK.DE) stock?

The dividend rating of RHOEN-KLINIKUM AG (RHK.DE) is 2 / 10 and the dividend payout ratio is 17.78%.